Neurogene Reports Promising Interim Results for NGN-401 Trial
Company Announcements

Neurogene Reports Promising Interim Results for NGN-401 Trial

Neurogene ( (NGNE) ) just unveiled an update.

Neurogene Inc. has reported promising interim results from its Phase 1/2 trial of NGN-401 gene therapy for Rett syndrome, highlighting improvements in key areas like motor skills and communication among the first four low-dose pediatric participants. The therapy, which has shown a favorable safety profile, marks significant progress as it addresses the core symptoms of this challenging neurodevelopmental disorder. The company plans to continue the trial with an adolescent/adult cohort and anticipates further updates in 2025, potentially paving the way for a commercial launch.

For detailed information about NGNE stock, go to TipRanks’ Stock Analysis page.

Related Articles
TheFlyNeurogene price target raised to $60 from $44 at Stifel
TheFlyNeurogene price target lowered to $60 from $65 at BMO Capital
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App